Simris Group (SIMRIS) investor relations material

Executive summary

• Net revenue for the year decreased by 44% to SEK 1,615k compared to the previous year, with Q4 revenue down 71% year-over-year.

• EBITDA for the year improved by 12% to SEK -15,539k, and EBIT improved by 15% to SEK -29,562k.

• Significant leadership changes occurred, including the appointment of an interim CEO and a new board member.

• The company is transitioning from food supplements to a biotech focus, with progress in preclinical ADC studies and a planned asset divestment.

Financial highlights

• Q4 net revenue was SEK 285k, down 71% year-over-year; full-year revenue was SEK 1,615k, down 44%.

• Q4 EBITDA was SEK -5,196k (down 63%); full-year EBITDA improved to SEK -15,539k (up 12%).

• Q4 EBIT improved by 9% to SEK -8,429k; full-year EBIT improved by 15% to SEK -29,562k.

• Cash at year-end was SEK 1,465k, down 25% from the prior year.

• Equity at year-end was SEK -470k, with solidity at -0.3%.

Outlook and guidance

• The board warns that current cash reserves may not be sufficient to fund operations through year-end and is actively seeking additional financing.

• The company is optimistic about closing the Hammenhög asset divestment and completing its transformation to a biotech company.

• ADC market is forecast to grow at a 10% CAGR into the 2030s, driven by expanded indications and increased pharma investment.